Korea Institute of Science and Technology

Industry-university Cooperation Foundation Hanyang University

Neurobiogen Co., Ltd.

Megabiowood Co., Ltd

Sun Joon Min

Ae Nim Pae

Jong-Hyun Park

Dong Jin Kim

Jun Young Heo

Ji Won Choi

Yun Kyung Kim

Yong Seo Cho

ChangJoon Justin Lee

Ki Duk Park

Jae Kyun Lee

Yong Koo Kang

Seul Ki Yeon

Hyun Ah Choo

Hyo Jung Song

Min Ho Nam

Bo Ko Jang

Eun Ji Ju

Seon Mi Jo

Youngjae Kim

Hyunah Choo

Seon Hee Seo

Jee Yeon Kim

Yeon Joon Park

Ji Yeong Kim

Ju Hyeon Kim

Yoo Ran Ki

Min Joo Kim

Sora Kim

Myung Hee Son

Eun Jeong Lim

Young Wook Son

Jong-hyun Park

The present disclosure relates to a compound represented by Chemical Formula 1, a probe for detecting antibiotic-resistant bacteria, which includes the compound, a composition containing the compound, a kit including the compound and a method for detecting antibiotic-resistant bacteria. A compound probe having a carbapenem structure and including a linker and a fluorophore can detect beta-lactamase or carbapenemase at high sensitivity and, therefore, can be applied to various biochemical researches. In addition, the compound probe can clinically detect carbapenemase-producing antibiotic-resistant bacteria and allows molecular diagnosis of antibiotic-resistant bacterial infectious diseases and analysis of antibiotic-resistant bacteria from a target sample at high sensitivity. Therefore, it can be effectively used for medicinal uses such as in-vitro diagnosis.

Probe for detecting carbapenem-resistant bacteria and use thereof

The present disclosure relates to an &#x3b1;-aminoamide derivative compound and a pharmaceutical composition containing the same. According to various embodiments of the present disclosure, provided is a therapeutic agent which can overcome the disadvantages of existing drugs used as a MAO-B inhibitor and, specifically, reversibly inhibits MAO-B through a non-covalent bond so as to alleviate or eliminate the side effects of the existing drugs which exhibit a therapeutic effect by irreversibly acting via a covalent bond with MAO-B. Particularly, a new compound having superior stability and efficacy compared to the existing reversible MAO-B inhibitors may be provided.

Alpha-aminoamide derivative compound and pharmaceutical composition comprising same

The present disclosure relates to an &#x3b1;-aminoamide derivative compound and a pharmaceutical composition containing the same, for treating a neurodegenerative diseases.

Disclosed are thienopyrimidinone derivatives as antagonists that act on metabotropic glutamate receptor subtype 1. The thienopyrimidinone derivatives show pharmacological activity against metabotropic glutamate receptor-related diseases, including pain, such as neuropathic pain and migraine, psychiatric diseases, such as anxiety disorder and schizophrenia, urinary incontinence, and neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease. Also disclosed are methods for preparing the thienopyrimidinone derivatives, and pharmaceutical compositions containing the thienopyrimidinone derivatives as active ingredients.

Thienopyrimidinone derivatives as mGluR1 antagonists

The present invention relates to a method for preparing tetrabenazine (TBZ) and dihydrotetrabenazine (DTBZ), and more specifically to a method for preparing tetrabenazine (TBZ) and dihydrotetrabenazine (DTBZ) by using simple and short reaction processes of using 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline and 4-methyl-2-(3-(trimethylsilyl)prop-1-ene-2-yl)pentane as starting materials to sequentially perform an alkylation reaction, an Aza-Prins cyclization reaction in the presence of an oxidant and an oxidation reaction.

Method of preparing tetrabenazine and dihydrotetrabenazine

Provided is a 2-(substituted ethynyl)quinoline derivative having an mGluR5 antagonistic activity and pharmaceutically acceptable salts thereof. The compound of the present invention can be useful as a medicament for treating and preventing mGluR5 receptor-mediated diseases such as Alzheimer's disease, senile dementia, Parkinson's disease, L-DOPA-induced dyskinesia, Huntington's chorea, amyotrophic lateral sclerosis, multiple sclerosis, schizophrenia, anxiety disorder, depression, neuropathic pain, drug dependence, fragile X syndrome, autism, migraine and gastroesophageal reflux disease (GERD).

2-(substituted ethynyl)quinoline derivatives as mGLUr5 antagonists

Growing community of inventors

Seoul, South Korea

Sun Joon Min